Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446101 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 450
- Enrollment target
NCT07446101 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants.
The verdict
NCT07446101, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 450 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-03-24 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446101
The ClinicalTrials.gov registry entry for NCT07446101 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT07446101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07446101 about?
NCT07446101 is a clinical study titled "A Study of Mirikizumab Solution (LY3074828) in Healthy Participants". The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the stud...
What is the current status of trial NCT07446101?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 450 participants. The study started on 2026-03-24. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07446101?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT07446101?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.